Alibaba Health Signs 30-Month Lease for 87,000 sq.m. Warehouse in Hangzhou
Reuters
Aug 28
Alibaba Health Signs 30-Month Lease for 87,000 sq.m. Warehouse in Hangzhou
Alibaba Health Information Technology Ltd. has announced a new lease agreement involving its wholly-owned subsidiary, Alibaba Health Pharmaceutical Chain, as the tenant. The lease, signed on August 28, 2025, is with Hangzhou Chuanfu and covers a production plant and ancillary facilities located at Alibaba Pharmaceutical Health Logistics Park in Hangzhou, PRC. The premises, with a floor area of approximately 87,000 square meters, will be used as a warehouse approved for the storage of pharmaceutical products and medical devices. This 30-month lease agreement is part of Alibaba Health's ongoing efforts to enhance its pharmaceutical and healthcare services, leveraging its digital technology to provide accessible and affordable healthcare solutions. The agreement was reached following arm's length negotiations, with terms deemed fair and aligned with market rates.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alibaba Health Information Technology Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.